AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review

AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH430057FSA
  • |
  • Pages: 70
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

AbbVie Inc (ABBV)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virology and metabolic therapy areas. The company also offers medicines for neurological disorders and other serious health conditions. AbbVie discovers and develops novel medicines based on protein-based and targeted drug delivery technologies. The company its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses across the world. AbbVie is headquartered in North Chicago, Illinois, the US.

AbbVie Inc Key Recent Developments

Jul 27,2018: AbbVie Reports Second-Quarter 2018 Financial Results

Jul 18,2018: AbbVie signs patent licensing deal with Mylan over Humira biosimilar

Jul 06,2018: Judge strikes USD140M AndroGel verdict after AbbVie appeal

May 23,2018: Big Pharma CMOs Win for Biologic API and Alcami Scores Highest for Biologic Drug Product

May 22,2018: AbbVie Donates USD100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

AbbVie Inc-Key Facts 6

AbbVie Inc-Key Employees 7

AbbVie Inc-Key Employee Biographies 8

AbbVie Inc-Major Products and Services 9

AbbVie Inc-History 11

AbbVie Inc-Company Statement 20

AbbVie Inc-Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Section 2-Company Analysis 30

Company Overview 30

AbbVie Inc-Business Description 31

Business Segment: Pharmaceuticals 31

Overview 31

Performance 31

Geographical Segment: All other countries 32

Performance 32

Geographical Segment: Brazil 32

Performance 32

Geographical Segment: Canada 32

Performance 32

Geographical Segment: France 32

Performance 32

Geographical Segment: Germany 32

Performance 32

Geographical Segment: Italy 33

Performance 33

Geographical Segment: Japan 33

Performance 33

Geographical Segment: Spain 33

Performance 33

Geographical Segment: The Netherlands 33

Performance 33

Geographical Segment: The UK 33

Performance 33

Geographical Segment: United States 33

Performance 33

R&D Overview 33

AbbVie Inc-Corporate Strategy 35

AbbVie Inc-SWOT Analysis 36

SWOT Analysis-Overview 36

AbbVie Inc-Strengths 36

AbbVie Inc-Weaknesses 37

AbbVie Inc-Opportunities 38

AbbVie Inc-Threats 39

AbbVie Inc-Key Competitors 40

Section 3-Company Financial Ratios 41

Financial Ratios-Capital Market Ratios 41

Financial Ratios-Annual Ratios 42

Performance Chart 45

Financial Performance 45

Financial Ratios-Interim Ratios 46

Financial Ratios-Ratio Charts 47

Section 4-Company's Lifesciences Financial Deals and Alliances 48

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 48

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 49

AbbVie Inc, Recent Deals Summary 50

Section 5-Company's Recent Developments 51

Jul 27, 2018: AbbVie Reports Second-Quarter 2018 Financial Results 51

Jul 18, 2018: AbbVie signs patent licensing deal with Mylan over Humira biosimilar 54

May 23, 2018: Big Pharma CMOs Win for Biologic API and Alcami Scores Highest for Biologic Drug Product 55

May 22, 2018: AbbVie Donates USD100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico 56

May 16, 2018: AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting 58

Apr 30, 2018: AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology 60

Apr 26, 2018: AbbVie Reports First-Quarter 2018 Financial Results 61

Mar 28, 2018: AbbVie pays USD5m to man who claims testosterone drug caused heart attack 63

Mar 28, 2018: AbbVie pays USD5m to man who claims testosterone drug caused heart attack 64

Mar 21, 2018: AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma 65

Section 6-Appendix 66

Methodology 66

Ratio Definitions 66

About GlobalData 70

Contact Us 70

Disclaimer 70

List of Figures

AbbVie Inc, Performance Chart (2013-2017) 45

AbbVie Inc, Ratio Charts 47

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 48

AbbVie Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 49

List of Tables

AbbVie Inc, Key Facts 6

AbbVie Inc, Key Employees 7

AbbVie Inc, Key Employee Biographies 8

AbbVie Inc, Major Products and Services 9

AbbVie Inc, History 11

AbbVie Inc, Subsidiaries 21

AbbVie Inc, Key Competitors 40

AbbVie Inc, Ratios based on current share price 41

AbbVie Inc, Annual Ratios 42

AbbVie Inc, Annual Ratios (Cont...1) 43

AbbVie Inc, Annual Ratios (Cont...2) 44

AbbVie Inc, Interim Ratios 46

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 48

AbbVie Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 49

AbbVie Inc, Recent Deals Summary 50

Currency Codes 66

Capital Market Ratios 66

Equity Ratios 67

Profitability Ratios 67

Cost Ratios 68

Liquidity Ratios 68

Leverage Ratios 69

Efficiency Ratios 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pfizer Inc

Novartis AG

Merck & Co Inc

Johnson & Johnson

GlaxoSmithKline Plc

Gilead Sciences Inc

Eli Lilly and Co

Bristol-Myers Squibb Co

Amgen Inc

AbbVie Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license
Single User License
USD 125 INR 8916
Site License
USD 250 INR 17833
Corporate User License
USD 375 INR 26749

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com